Combination therapy for dyslipidemia

Current Opinion in Cardiology

Volumn 26, Issue 5, 2011, Pages 420-423

  Sharma, Mukul ^a  

^a UNIVERSITY OF OTTAWA   (Canada)

Author keywords

combination therapy; dyslipidemia; ezetimibe; fenofibrate; niacin

Indexed keywords

ACETYLSALICYLIC ACID; BILE ACID SEQUESTRANT; EZETIMIBE; EZETIMIBE PLUS SIMVASTATIN; FENOFIBRATE; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LAROPIPRANT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; SIMVASTATIN; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADD ON THERAPY; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTERIAL WALL THICKNESS; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHEMOPROPHYLAXIS; CHOLESTEROL BLOOD LEVEL; COMBINATION CHEMOTHERAPY; CONSTIPATION; CREATINE KINASE BLOOD LEVEL; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSLIPIDEMIA; FLUSHING; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERCHOLESTEROLEMIA; LOW DRUG DOSE; MONOTHERAPY; MYALGIA; PRIORITY JOURNAL; REVIEW; RHABDOMYOLYSIS; RISK REDUCTION; SIDE EFFECT; SYSTEMATIC REVIEW; TACHYCARDIA; TACHYPHYLAXIS; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL;

ANTICHOLESTEREMIC AGENTS; AZETIDINES; DRUG THERAPY, COMBINATION; DYSLIPIDEMIAS; FIBRIC ACIDS; HUMANS; NIACIN;

EID: 80051729855     PISSN: 02684705     EISSN: 15317080     Source Type: Journal    
DOI: 10.1097/HCO.0b013e3283499ef1     Document Type: Review

References (26)

1. Cholesterol Treatment Trialists' Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: A meta-analysis of data from 170 000 participants in 26 randomized trials. Lancet 2010; 376: 1670-1681. This is an updated meta-analysis of the effect of LDL lowering to lower targets.
2. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP). JAMA 2001; 285:2486-2497.
3. Garcia-Calvo M, Lisnock J, Bull HG, et al. The target of ezetimibe is Niemann- Pick C1-Like 1 (NPC1L1). Proc Natl Acad Sci USA 2005; 102:8132-8137.
4. Knopp RH, Dujovne CA, Le BA, et al. Evaluation of the efficacy, safety, and tolerability of ezetimibe in primary hypercholesterolaemia: A pooled analysis from two controlled phase III clinical studies. Int J Clin Pract 2003; 57:363-368.
5. Sharma M, Ansari MT, Abou-Setta AM, et al. Systematic review: Comparative effectiveness and harms of combination therapy and monotherapy for dyslipidemia. Ann Intern Med 2009; 151:622-630. A comprehensive review of all options for combination therapy on surrogate and clinical endpoints.
6. Kastelein J, Akdim F, Stroes E, et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med 2008; 358:1431-1443.
7. Taylor AJ, Villines MD, Stanek EJ, et al. Extended release niacin or ezetimibe and carotid intima media thickness. N Engl J Med 2009; 361:2113-2122.
8. Baigent C, Landray M, Collins R, et al. The study of heart and renal protection (SHARP) results. In: Proceedings of the American Society of Nephrology; 10 November 2010; Denver, Colorado.
9. Baigent C, Landray M, Reith C, et al. The effects of lowering LDL with simvastatin and ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): A randomized placebo controlled trial. Lancet 2011; 377:2181-2192.
10. SHARP Collaborative Group. Study of heart and renal protection (SHARP): Randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9438 patients with chronic kidney disease Am Heart J 2010; 160:785-794.
11. Fleg JL, Mete M, Howard BV, et al. Effect of statins alone versus statins plus ezetimibe on carotid atherosclerosis in type 2 diabetes: The SANDS trial. J Am Coll Cardiol 2008; 52:2198-2205.
12. Shepherd J, Packard CJ, Patsch JR, et al. Effects of nicotinic acid therapy on plasma high density lipoprotein subfraction distribution and composition and on apolipoprotein A metabolism. J Clin Invest 1979; 63:858-867.
13. Sakai T, Kamanna VS, Kashyap ML. Niacin, but not gemfibrozil, selectively increases LP-AI, a cardioprotective subfraction of HDL, in patients with low HDL cholesterol. Arterioscler Thromb Vasc Biol 2001; 21:1783-1789.
14. Birjmohun RS, Hutten BA, Kastelein JJ, et al. Increasing HDL cholesterol with extended-release nicotinic acid: From promise to practice. Neth J Med 2004; 62:229-234.
15. Castelli WP, Garrison RJ, Wilson PW, et al. Incidence of coronary heart disease and lipoprotein cholesterol levels: The Framingham Study. JAMA 1986; 256:2835-2838.
16. Ruparelia N, Digby JE, Choudhary RP. Effects of niacin on atherosclerosis and vascular function. Curr Opin Cardiol 2011; 26:66-70.
17. http://www.nih.gov/news/health/may2011/nhlbi-26.htm. [Accessed 29 May 2011]
18. Singh IM, Shishehbor MH, Ansell BJ. High-density lipoprotein as a therapeutic target: A systematic review. JAMA 2007; 298:786-798. Excellent review of the biology and therapeutic mechanisms available to influence HDL.
19. Staels B, Dallongeville J, Auwerx J, et al. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation 1998; 98:2088-2093.
20. Barter PJ, RyeKA. Is there a role for fibrates in themanagement of dyslipidemia in the metabolic syndrome? Arterioscler Thromb Vasc Biol 2008; 28:39-46.
21. Goldenberg I, Benderly M, Goldbourt U. Update on the use of fibrates: Focus on bezafibrate. Vasc Health Risk Manag 2008; 4:131-141.
22. Grundy SM, Hansen B, Smith SC Jr, et al. Clinical management of metabolic syndrome: Report of the American Heart Association/National Heart, Lung, and Blood Institute/American Diabetes Association conference on scientific issues related to management. Circulation 2004; 109:551-556.
23. The ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010; 362:1563-1574.
24. Anonymous. The lipid research clinics coronary primary prevention trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 1984; 251:365-374.
25. Insull J. Clinical utility of bile acid sequestrants in the treatment of dyslipidemia: A scientific review. South Med J 2006; 99:257-273.
26. Guyton JR, Brown G, Fazio S, et al. Lipid-altering efficacy and safety of simvastatin/ezetimibe coadministered with extended-release niacin in patients with type 2a or 2b hyperlipidemia. J Am Coll Cardiol 2008; 51:1564-1572.